Menu
Search
|

Menu

Close
X

Innoviva Inc INVA.OQ (NASDAQ Stock Exchange Global Select Market)

13.95 USD
-- (--)
As of Mar 21
chart
Previous Close 13.95
Open --
Volume --
3m Avg Volume 355,121
Today’s High --
Today’s Low --
52 Week High 20.53
52 Week Low 13.27
Shares Outstanding (mil) 109.36
Market Capitalization (mil) 1,566.05
Forward P/E 20.00
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
261
FY17
217
FY16
134
EPS (USD)
FY18
3.486
FY17
1.120
FY16
0.441
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
20.00
32.54
Price to Sales (TTM)
vs sector
8.90
8.39
Price to Book (MRQ)
vs sector
--
5.27
Price to Cash Flow (TTM)
vs sector
14.71
24.12
Total Debt to Equity (MRQ)
vs sector
--
16.02
LT Debt to Equity (MRQ)
vs sector
--
11.35
Return on Investment (TTM)
vs sector
26.11
13.82
Return on Equity (TTM)
vs sector
--
15.25

EXECUTIVE LEADERSHIP

William Waltrip
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Geoffrey Hulme
Interim Principal Executive Officer, Since 2018
Salary: --
Bonus: --
Marianne Zhen
Chief Accounting Officer, Since 2018
Salary: --
Bonus: --
Mark DiPaolo
Director, Since 2018
Salary: --
Bonus: --
Jules Haimovitz
Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2000 Sierra Point Pkwy Ste 500
BRISBANE   CA   94005-1830

Phone: +1650.2389600

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

SPONSORED STORIES